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MaBACKGROUND Exposure of blood to polyanionic artificial surfaces, for example, during cardiopulmonary bypass (CPB),
induces a highly procoagulant condition requiring strong anticoagulation. Unfractionated heparin (UFH) is currently used
during CPB but can lead to serious bleeding complications or development of a hypercoagulable state culminating in life-
threatening thrombosis, highlighting the need for safer antithrombotics. Ixodes ricinus contact phase inhibitor (Ir-CPI) is a
protein expressed by I. ricinus ticks, which specifically inhibits both factors XIIa and XIa, 2 factors contributing to
thrombotic disease while playing a limited role in hemostasis.
OBJECTIVES This study assessed the antithrombotic activity of Ir-CPI in animal contact phase-initiated thrombosis
models, including CPB. The safety of Ir-CPI also was evaluated.
METHODS The authors evaluated the antithrombotic activity of Ir-CPI by using in vitro catheter-induced clotting assays
and rabbit experimental models of catheter occlusion and arteriovenous shunt. During CPB with cardiac surgery in sheep,
the clinical applicability of Ir-CPI was investigated and its efficacy compared to that of UFH using an uncoated system
suitable for adult therapy. Taking advantage of the similar hemostatic properties of pigs and humans, the authors per-
formed pig liver bleeding assays to evaluate the safety of Ir-CPI.
RESULTS Ir-CPI prevented clotting in catheter and arteriovenous shunt rabbit models. During CPB, Ir-CPI was as effi-
cient as UFH in preventing clot formation within the extracorporeal circuit and maintained physiological parameters
during and post-surgery. Unlike UFH, Ir-CPI did not promote bleeding.
CONCLUSIONS Preclinical animal models used in this study showed that Ir-CPI is an effective and safe
antithrombotic agent that provides a clinically relevant approach to thrombosis prevention in bypass systems,
including highly thrombogenic CPB. (J Am Coll Cardiol 2019;74:2178–89) © 2019 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C ardiopulmonary bypass (CPB) is commonlyrequired during complex cardiac surgical in-terventions. It is a life support procedure
that exposes blood to nonphysiological shear stress,
turbulences, and osmotic forces as well as interaction
with polyanionic artificial surfaces, promotingN 0735-1097
m aBioxodes S.A., Marche-en-Famenne, Belgium; bIMM Recherche, Institu
., Namur, Belgium; and dGIGA Cardiovascular Sciences, Department of
man, Liège, Belgium. This work was supported by grants from the Walloo
nder and CEO of QUALIblood S.A.; and has received personal fees from D
d Daiichi-Sankyo. All other authors have reported that they have no rel
close. Frits R. Rosendaal, MD, PhD, served as Guest Associate Editor for
nuscript received July 8, 2019; accepted August 1, 2019.undesirable contact phase coagulation. Anticoagulant
drugs such as unfractionated heparin (UFH) are
currently used during CPB to prevent thrombotic oc-
clusions within the oxygenator and tubing of the
extracorporeal circuit. However, UFH is frequently
associated with hemorrhagic side effects because ithttps://doi.org/10.1016/j.jacc.2019.08.1028
t Mutualiste Montsouris, Paris, France; cQUALIblood
Cardiology, University Hospital of Liège, CHU Sart
n Region (convention 6823 and 7336). Dr. Douxfils is
iagnostica Stago, Roche, Roche Diagnostics, Portola,
ationships relevant to the contents of this paper to
this paper.
AB BR E V I A T I O N S
AND ACRONYM S
ACT = activated clotting time
aPTT = activated partial
thromboplastin time
CPB = cardiopulmonary bypass
FXI = factor XI
FXIa = factor XIa
FXII = factor XII
FXIIa = factor XIIa
Ir-CPI = Ixodes ricinus contact
phase inhibitor
SEM = standard error of the
mean
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Author's Personal Copytargets key proteases in the coagulation cascade that
initiate fibrin generation (1,2). Use of UFH can also
be associated with the development of platelet-
activating antibodies that induce thrombocytopenia
and generate a hypercoagulable state that increases
the propensity for life-threatening thrombosis (3).
Furthermore, large variabilities in the response to
UFH, assessed by determination of the activated clot-
ting time (ACT), and resistance to the drug have been
reported. Heparin resistance has been notably
observed in patients undergoing cardiovascular oper-
ations that require CPB (4,5). Thus, the search for new
anticoagulants that prevent thrombus formation
without increasing hemorrhage risk is a major chal-
lenge in medicine.SEE PAGE 2190
IU = international unit
UFH = unfractionated heparinTargeting factor XII (FXII) of the contact phase or
factor XI (FXI) involved in the intrinsic pathway of
coagulation is an alternative to current anticoagu-
lants that usually target zymogens or proteases
belonging to the common pathway. It has been shown
in animal models that FXII and FXI deficiencies/in-
hibition protect against thrombosis without causing
spontaneous bleeding (6–11). FXII and FXI inhibitions
were also reported to reduce experimental thrombus
formation in primates (12–14). Moreover, there is ev-
idence supporting a role for FXI in arterial and venous
thrombosis in humans (15–17). Importantly, no
bleeding tendency has been reported in patients with
severe deficiencies of FXII, prekallikrein, or high-
molecular-weight kininogen (18). Patients with such
deficiencies do not require any form of therapy before
surgery despite showing a paradoxically prolonged
activated partial thromboplastin time (aPTT). In
contrast, FXI-deficient patients have a relatively mild
bleeding disorder. In these patients, spontaneous
bleedings are rare, and bleeding typically occurs after
surgery or injury and particularly affects tissues with
high fibrinolytic activity (oral and nasal cavities,
tonsils, genitourinary tract) (19). Therefore, these
observations indicate that drugs targeting FXII or FXI
would be associated with better control of hemostasis
than current anticoagulants.
Ticks are well known to produce salivary substances
that neutralize the hemostatic system of the host for
successful blood feeding (20). Decrem et al. (21) pre-
viously characterized a serine protease inhibitor from
the salivary glands of the tick Ixodes ricinus. This pro-
tein, called Ixodes ricinus contact phase inhibitor
(Ir-CPI), has 1 Kunitz domain and specifically binds
both factor XIIa (FXIIa) and factor XIa (FXIa) (21).
In vitro, Ir-CPI was reported to prolong aPTT, showing
interference with the intrinsic pathway while havingno effect on prothrombin time, thrombin time,
and the dilute Russell’s viper venom time, 3
tests that trigger blood coagulation with acti-
vators of the extrinsic or common pathways.
In reconstituted systems, Ir-CPI was shown to
prevent activation of FXI and FXII. These
mechanistic studies strongly suggest that Ir-
CPI is a specific inhibitor of both FXIIa and
FXIa. In vivo studies with rodent pro-
thrombotic models showed that Ir-CPI inhibits
the formation of both venous and arterial
thrombi without disturbing the clotting bal-
ance (21).
In this study using animal models (i.e.,
accelerated-catheter thrombosis, arteriove-
nous shunt, and CPB with cardiac surgery), we
assessed the clinical applicability of Ir-CPI as
an antithrombotic agent when thrombosis is predom-
inantly a contact phase-driven event. Based on these
results, we deduced that Ir-CPI is safer than UFH
because it can inhibit the formation of thrombiwithout
increasing bleeding risk.
METHODS
Four different animal models were used (see the
Online Appendix for further details). The in vitro
coronary guiding catheter-induced clotting assay and
the accelerated catheter thrombosis model in rabbits
were an adaptation of the method described by Yau
et al. (22). The rabbit arteriovenous shunt model was
adapted from Wong et al. (23).
CPB AND CARDIAC SURGERY PROCEDURE. A total of
10 anesthetized female sheep (38 to 45 kg) underwent
CPB, using only uncoated material, with cardiac sur-
gery. Cannulas inserted in the carotid artery and ju-
gular vein were connected to a circuit that included
tubing, a rotating pump, and an oxygenator with a
hard-shell venous reservoir. A mechanical roller pump
circulated the blood through the circuit. CPB was
maintained at a full-flow systemic perfusion level.
Oxygenator pressure gradients were continuously
measured as rapid markers of oxygenator clotting.
After pericardium and left atrium opening, a mitral
chordae was replaced and a commissuroplasty of the
mitral valve was performed. Venting was achieved by
reducing CPB enough to fill the left atrium and
ventricle. The atrium was sutured, and the CPB flow
level was slowly reduced. In recovery animals, a chest
tube was inserted for pleural drainage, the thorax was
closed, and analgesia was provided.
For Ir-CPI–treated animals (n ¼ 3 þ 2 recovery),
priming of the circuit was performed with a solution
containing Ir-CPI (7.5 or 10.5 mg/l). Ir-CPI was
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Author's Personal Copyintravenously injected with a bolus (4.6 or 6.5 mg/kg)
immediately followed by an infusion (3.2 or
4.5 mg/kg/h), just before the thoracotomy. The infu-
sion lasted until the end of the procedure. After
pericardium opening and before cannulation,
comparative animals (n ¼ 3 þ 2 recovery) received an
intravenous bolus of 100 IU/kg of UFH to target an
ACT of 715 s (human equivalent ACT: 420 s).
For experiments that included a recovery period,
animals were clinically followed-up until their sacri-
fice on day 7. For both nonrecovery and recovery ani-
mals, an autopsy including macroscopic and
microscopic examinations was performed. For micro-
scopic analyses, standard samples from the heart,
kidney, lung, liver, and brain were submitted to his-
tological evaluation. In addition, spleen and draining
lymph nodes were analyzed in recovery animals.
LIVER BLEEDING MODEL. A sagittal subxiphoid
laparotomy was performed to access the liver lobes of
anesthetized pigs weighing 48 to 76 kg. Wounds of
4-mm diameter and 3-mm depth were made with
biopsy punches under NaCl 0.9%, Ir-CPI, or UFH
treatment. The weight of blood collected in the gauze
compresses placed near the biopsies was measured.
After saline treatment, animals received UFH or
Ir-CPI. UFH dosage administered was 50 IU/kg or
100 IU/kg (bolus), followed 15 min later by a second
half-dose bolus (50 or 25 IU/kg). Additional half-doses
of UFH (50 or 25 IU/kg) were administered when
required to obtain ACT of 630 or 240 s (human-
equivalent ACT: 420 or 160 s, respectively). For Ir-
CPI–treated animals, the investigational drug was
intravenously injected with a bolus (4.6 mg/kg) fol-
lowed by a continuous infusion (3.2 mg/kg/h) before
the first wound was made.
STATISTICAL ANALYSIS. Normally distributed data
are expressed as mean  SEM, where n represents the
number of animals (see the Online Appendix for
further details).
RESULTS
Ir-CPI DELAYS CATHETER-INDUCED CLOT FORMATION
IN VITRO AND IN VIVO. The mean clotting time 50
(defined as the time corresponding to one-half
maximal absorbance) of platelet-poor plasma was
1.9-fold shorter in the presence of catheter segments
than in their absence (821  12 s and 1,523  55 s;
n ¼ 3; p < 0.001), confirming that coronary guiding
catheter segments exert a prothrombotic activity
(Figures 1A and 1B). Ir-CPI linearly increased the
clotting time as a function of its concentration
(Figure 1B). The effect of Ir-CPI on catheter-inducedclotting was then explored in FXII- or FXI-deficient
plasma. No catheter-induced clotting was observed
in FXI-deficient plasma (data not shown). Ir-CPI
decreased and even prevented (23 mg/ml) catheter-
induced clotting in FXII-deficient plasma (Figure 1C).
In platelet-poor plasma, thrombin generation was
higher in the presence of catheter segments than in
their absence (i.e., Hepes [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid] condition)
(Figure 1D). The presence of catheter segments
shortened (2.0-fold) the time to generation of
thrombin (lag time) and increased (2.1-fold) the
endogenous thrombin potential (Figures 1E and 1F). Ir-
CPI dose-dependently decreased the generation of
thrombin and the endogenous thrombin potential,
and increased the lag time in plasma incubated with
catheter segments (Figures 1D to 1F).
In a rabbit model of accelerated catheter throm-
bosis, thrombus formation induced by repeated
flushes was monitored via the increase of pressure
resistance in the catheter. When compared to saline-
treated animals, the time to catheter occlusion was
significantly prolonged in all Ir-CPI–treated rabbits,
with a minimal prolongation of 2.3-fold at 1 mg/kg
(61  2.5 min; n ¼ 3; p < 0.05) and maximal prolon-
gation of 4.5-fold at 18 mg/kg (117.3  7.2 min; n ¼ 3;
p < 0.05) (Figure 2A). With doses of 1, 5, and 18 mg/kg
of Ir-CPI, the plasma levels after the catheter
occlusion procedure were 1.0  0.3, 2.8  0.6, and
9.0  0.4 mg/ml (n ¼ 3 per concentration) (Figure 2B).
Ir-CPI INTERFERES WITH THROMBUS FORMATION IN
A RABBIT ARTERIOVENOUS SHUNT MODEL. The
antithrombotic action of Ir-CPI was evaluated in
rabbits using an arteriovenous shunt model wherein
a total inhibition of thrombus formation was ob-
tained under UFH treatment (300 IU/kg; data not
shown). In saline-treated animals (control group),
the mean thrombus weight was 177.5  14.1 mg
(n ¼ 6) (Figure 3A). Injection of Ir-CPI resulted in a
dose-dependent and significant decrease of clot
weight. In rabbits, 1, 3, and 5 mg/kg doses of Ir-CPI
resulted in clot weight decreases of 37%
(p ¼ 0.078), 62% (p < 0.05), and 97% (p < 0.001),
respectively (Figure 3A). At 5 mg/kg, 2 of 3 animals
did not show any thrombus formation. At the end of
the procedure (t ¼ 40 min), the mean aPTT ratio was
0.99  0.01 (n ¼ 4) in the control group (Figure 3B).
A single bolus administration of Ir-CPI increased the
aPTT ratio by 25% (p < 0.01), 40% (p < 0.001), and
52% (p < 0.001) at 1, 3, and 5 mg/kg, respectively
(Figure 3B). Injection of Ir-CPI at $3 mg/kg increased
significantly (p < 0.001) the percentages of inhibi-
tion of FXII and FXI procoagulant activities
FIGURE 1 Effect of Ir-CPI on the Prothrombotic Activity of Catheters In Vitro
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FIGURE 2 Effect of Ir-CPI on the Time to Catheter Occlusion in Rabbits
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(A) Rabbits were given saline or Ir-CPI intravenously before the beginning of catheter flushing. Thereafter, every 5 min, blood was withdrawn
into the catheter, held in a syringe, and slowly reinjected until total occlusion of the catheter. (B) Ir-CPI plasma concentration after catheter
occlusion. Results are expressed as mean  SEM of 3 experiments. One-way analysis of variance statistical analysis with Dunnett multiple
comparison test was used. p < 0.05; **p < 0.01. Ir-CPI ¼ Ixodes ricinus contact phase inhibitor.
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Author's Personal Copycompared to the saline-treated group (Figures 3C and
3D). With an injected dose of 5 mg/kg of Ir-CPI,
percentages of inhibition of FXI and FXII procoagu-
lant activities were 44.2  1.5% (n ¼ 3) and
36.2  2.1%, respectively. Mean Ir-CPI plasma levels
were 0.9, 2.8, and 4.2 mg/ml at 40 min post-
intravenous injection after administration of 1, 3,
and 5 mg/kg of Ir-CPI, respectively (Figure 3E).
Ir-CPI CONFERS THROMBOPROTECTION DURING
CPB IN CARDIAC SURGERY ON BEATING HEART. To
investigate the clinical relevance of Ir-CPI in throm-
bosis prevention, we used CPB in cardiac surgery on
beating heart. Mitral chordae replacement and com-
missuroplasty were performed under CPB in healthy
sheep treated with Ir-CPI or UFH used as comparative
drug. Time of overall procedure was between 40 to
106 min in Ir-CPI–treated sheep and 34 to 54 min in
UFH-treated sheep. In untreated sheep, total
obstruction of the arterial cannula at the cannulation
site occurred in less than 2 min, and CPB could not be
performed. In contrast, Ir-CPI and the comparative
drug, UFH, prevented occlusion of the CPB system in
all animals.
At the start of CPB, mean Ir-CPI plasma concen-
tration was 9.4  1.9 mg/ml (n ¼ 5). Corresponding
mean percentage of inhibition of FXII procoagulant
activity was 83.8  2.9% (n ¼ 5). Ir-CPI plasma con-
centration and FXII inhibition remained stable during
the overall procedures (Figures 4B and 4C).In animals injected with Ir-CPI, pressure in the
venous and arterial lines and blood pressure gradient
over the oxygenator remained constant throughout
the procedure, indicating no functional obstruction of
the oxygenators (Figure 4B). Gas exchange parameters
also remained constant during CPB. No statistical
differences were observed with regard to partial arte-
rial pressure of oxygen (PaO2), partial arterial pressure
of carbon dioxide (PaCO2), and arterial oxygen satura-
tion (SaO2) values between Ir-CPI– and UFH-treated
sheep during the overall procedure (Online Table 1).
SaO2 reached 99% to 100% in both groups of sheep and
was stable throughout the procedure, demonstrating
efficient oxygenation (Online Table 1).
Standard clinical hematology and biochemistry
markers showed similarmodifications of values during
the procedures in Ir-CPI– and UFH-treated animals. In
both groups, parameters fully or partially recovered by
the end of the recovery period (day 7) (Online Figures 1
to 3). Only erythrocyte and reticulocyte counts as well
as hemoglobin and hematocrit concentrations took
longer to recover in animals treated with Ir-CPI than in
animals treated with UFH (Online Figure 4).
Thrombosis on oxygenator membranes was evalu-
ated by scanning electron microscopy. Traces of fibrin
were occasionally observed between oxygenator
capillaries in membranes of Ir-CPI– and UFH-treated
sheep. In the Ir-CPI group, rare blood cells were also
observed between fibers (Figure 4A).
FIGURE 3 Effect of Ir-CPI in a Rabbit Model of Arteriovenous Shunt Thrombosis
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Rabbits were intravenously treated with a bolus of saline or Ir-CPI (1, 3, or 5 mg/kg), followed by an infusion of saline 5 min before the start of shunt perfusion until the
end of the procedure (t ¼ 40 min). Thrombus weight (A), aPTT ratio (B), percentages of inhibition of FXII (C) and FXI (D) procoagulant activity, and Ir-CPI plasma
concentration (E) at t ¼ 40 min in saline- or Ir-CPI–treated animals. Data are expressed as mean  SEM with sample size (n). One-way analysis of variance statistical
analysis with Dunnett multiple comparison test was used. *p < 0.05; **p < 0.01; ***p < 0.001. aPTT ¼ activated partial thromboplastin time; FXI ¼ factor XI;
FXII ¼ factor XII; Ir-CPI ¼ Ixodes ricinus contact phase inhibitor; PBS ¼ phosphate-buffered saline.
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FIGURE 4 Antithrombotic Effect of Ir-CPI and UFH During CPB
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Ir-CPI–treated sheep were intravenously injected with a bolus of Ir-CPI (4.6 to 6.5 mg/kg), followed by an infusion (3.2 to 4.5 mg/kg/h) 30 min before the start of CPB.
Another group of animals received UFH (100 IU/kg). (A) Scanning electron microscopy representative images of gas-exchanging capillaries of oxygenator membranes
for nonrecovery animals treated with Ir-CPI or UFH. Arrows point to either blood cells or fibrin deposits between fibers. Magnification 35 to 1,000. (B) Changes in
blood pressure gradients over the oxygenator for animals treated with UFH or Ir-CPI. Mean  SEM (n ¼ 5 from 1 to 30 min and n ¼ 2 or 3 from 40 to 70 min).
(C) Percentage of FXII procoagulant activity inhibition (mean  SEM). CPB ¼ cardiopulmonary bypass; IU ¼ international unit; UFH ¼ unfractionated heparin; other
abbreviations as in Figure 3.
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Author's Personal CopyFollowing CPB and cardiac surgery procedures,
unsacrificed animals from the Ir-CPI and UFH
groups had a normal recovery, and no specific
clinical observations were made until their sacrifice
on day 7. After macroscopic and microscopic ana-
lyses in organs of nonrecovery and recovery animalssacrificed at day 0 or day 7, respectively, neither Ir-
CPI– nor UFH-related findings, including relevant
inflammatory changes, were observed.
Ir-CPI DOES NOT INDUCE BLEEDING IN A PIG
MODEL. The bleeding effect of Ir-CPI andUFH, used as
comparative drug, was investigated in a pig model by
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Author's Personal Copyperforming lesions with a biopsy punch in liver lobes.
At the start of lesions, mean Ir-CPI plasma concentra-
tion was 8.5  1.0 mg/ml (n ¼ 4), and mean inhibition of
FXII procoagulant activity was 70.9  0.8% (n ¼ 4). Ir-
CPI concentration and FXII inhibition remained stable
during the overall procedures (Figure 5A).
Blood loss weight in saline-treated control animals
was 3.4  0.7 g (n ¼ 44). No statistical difference was
observed with Ir-CPI–treated animals (13.2  4.1 g;
n ¼ 18), whereas blood loss weight was significantly
higher (p<0.001) in UFH-treated animals (34.6 7.8 g;
n ¼ 31; and 57.3  11.7 g; n ¼ 20; with 50 þ 25 IU/kg or
100 þ 50 IU/kg). Moreover, blood loss weight was sta-
tistically higher (p < 0.01) in animals treated with UFH
(100 þ 50 IU/kg) than in those treated with Ir-CPI
(Figure 5B). Finally, bleeding was systematically
observed on previously cauterized wounds under
UFH treatment. This phenomenon was not observed
at cauterized wound sites in Ir-CPI–treated animals.
DISCUSSION
There is a medical need to find safer antithrombotic
treatments in patients undergoing cardiovascular
interventions. In our study, Ir-CPI was proven to be
as efficient as UFH during CPB in cardiac surgery and
to be a safe antithrombotic compound.
Previous studies showed that Ir-CPI specifically
binds to both FXIIa and FXIa. In vitro, this molecule
prolongs aPTT and inhibits thrombin generation
induced by activators of the contact phase (ellagic
acid and phospholipids), whereas it has no effect on
prothrombin time, thrombin time, and dilute Rus-
sell’s viper venom time. Ir-CPI is known to prevent
activation of FXI into FXIa by FXIIa and activation of
FXII into FXIIa by FXIa (21). In vivo effects of Ir-CPI
were previously examined using both venous and
arterial thrombosis models. Intravenous administra-
tion of Ir-CPI in rats and mice resulted in a dose-
dependent reduction of arterial and venous
thrombus formation (21). Moreover, treated mice
were protected against collagen- and epinephrine-
induced thromboembolism (21).
In this study, we evaluated the potential
antithrombotic effect of Ir-CPI in preclinical contact
phase-driven thrombosis models with increasing
complexity. Catheters such as those used during
percutaneous coronary intervention are procoagulant,
and we and other investigators (22) showed that the
capacity of catheter segments to promote clotting is
dramatically attenuated or abrogated in both human
FXI and FXII-deficient plasmas, suggesting that the
prothrombotic effect of catheters depends on these
key components. Using human plasma, we showedthat Ir-CPI dose-dependently delays catheter-induced
clot formation but also delays and reduces catheter-
induced thrombin generation. Using a rabbit model
of accelerated catheter thrombosis, we showed that Ir-
CPI has also dose-dependent antithrombotic proper-
ties. Moreover, protection against thrombus forma-
tion by Ir-CPI was also observed when the
arteriovenous shunt model was used. Decrease of
thrombus weight was observed in Ir-CPI–treated ani-
mals (97% of thrombus weight reduction at 5 mg/kg).
At the end of the procedure, with an injected dose of
5 mg/kg of Ir-CPI, aPTT ratio was increased by 52%,
and mean percentages of inhibition of FXI and FXII
procoagulant activities were 44% and 36%, respec-
tively. Results are consistent with the antithrombotic
effects documented for rHA-Infestin-4, another ther-
apeutic protein inhibiting FXIIa, with antisense FXI or
FXII oligonucleotides, and with monoclonal anti-
bodies inhibiting either FXIIa or FXIa activity in the
arteriovenous shunt model performed in various
species (10,13,14,24). Nevertheless, in the latter
studies, almost complete or complete abolition of
thrombus formation was obtained with FXI or FXII
inhibition superior to 80%. This may suggest that dual
FXII and FXI inhibition offers an advantage over single
clotting factor inhibition.
We further assessed the efficacy of Ir-CPI in an
animal model closer to a clinical indication. Ovine
and porcine models accurately simulate characteris-
tics of human anatomy, physiology, and hemostatic
properties (25). Using CPB associated with 2 cardiac
procedures on beating heart, namely, mitral chordae
replacement and commissuroplasty of the mitral
valve performed on healthy sheep (Central
Illustration), we showed that Ir-CPI is as efficient as
UFH in preventing clot formation and maintaining
physiological parameters. In this model, Ir-CPI con-
fers its thromboprotection with a mean inhibition of
FXII procoagulant activity of 84%. During the overall
procedure, blood gas parameters (PaO2, PaCO2, and
SaO2) remained stable, demonstrating efficient
oxygenation. Pressure in the venous and arterial lines
and blood pressure gradient over the oxygenator
remained unchanged throughout the procedure,
indicating no functional obstruction of the oxygena-
tors. For standard hematology or biochemistry
markers, modifications of values have been similarly
observed in both groups, suggesting that changes
were associated with the procedure (e.g., hemodilu-
tion effect) rather than the treatment. In both groups,
these parameters fully or partially recovered. Never-
theless, erythrocyte and reticulocyte counts as well
as hemoglobin and hematocrit concentrations took
longer to recover in animals treated with Ir-CPI than
FIGURE 5 Effects of Ir-CPI and UFH on Bleeding
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Animals were first treated with saline. Next, animals were treated with either Ir-CPI or UFH. Ir-CPI–treated pigs were intravenously injected with a bolus (4.6 mg/kg)
followed by an infusion (3.2 mg/kg/h) 30 min before the first wound was made. UFH-treated pigs received either 50 IU/kg or 100 IU/kg, followed 15 min later by a
second half-dose (50 or 25 IU/kg). Additional half-dose UFH administrations (50 or 25 IU/kg) were given when required to reach the target activated clotting time.
(A) Percentage of FXII procoagulant activity inhibition. (B) Blood loss weight obtained until clotting of the wound or during a maximal period of 25 min in saline-,
UFH- or Ir-CPI–treated animals. Data are expressed as mean  SEM with sample size. Kruskal-Wallis statistical analysis with Dunn multiple comparison test was used.
**p < 0.01; ***p < 0.001. Abbreviations as in Figures 3 and 4.
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Author's Personal Copyin animals treated with UFH. This phenomenon was
likely related to the high number of blood samplings
performed during procedures in animals treated
with Ir-CPI. Oxygenator membrane examination by
scanning electron microscopy showed no differences
between Ir-CPI and UFH groups in terms of protein
or blood cell deposits. Full recovery was obtained
after CPB and cardiac surgery with no related-Ir-CPI
findings and no relevant inflammatory changes
observed after organ macroscopic and microscopic
analyses.
Both FXI and FXII knockdown have already been
reported to be effective in preventing clotting on
artificial surfaces such as catheters in rabbits (26).
Furthermore, Larsson et al. (10) showed that the use
of a monoclonal immunoglobulin G targeting FXIIa
resulted in maintenance of physiological parameters
(plasma pH, oxygen saturation) and circuit blood flow
during a 6-hour ECMO-like procedure in rabbits
without increasing bleeding. However, no recovery
animals were included in that study, so no conclu-
sions can be made about its efficacy and safety and
thus its clinical applicability in such a procedure.In order to simulate the worst-case scenario, the
extracorporeal circuits used in our study were un-
coated, thus excluding any hemocompatibility of the
circuit and protection of blood activation by the ma-
terial surface. Moreover, other than coagulation
activation, another complication witnessed during
CPB, notably with an uncoated circuit, is the inflam-
matory response. Indeed, exposure of a patient’s
blood to the nonendothelialized surface of the circuit,
surgical trauma, or ischemia/reperfusion injury re-
sults in widespread activation of the innate immune
system (27). Thus, in the CPB model, Ir-CPI acts in a
highly inflammatory and thrombogenic environment
in which the contact phase is strongly activated by
exposure of blood to the surface of the extracorporeal
unit, the oxygenator, pump, and connections be-
tween the animal and the extracorporeal device.
Thrombin generation is also mediated by activation of
the tissue factor-dependent extrinsic pathway
through exposure of blood to air and tissue factor
secretion in the wound. Therefore, the results indi-
cated that Ir-CPI still is efficacious in a complex sys-
tem involving both the intrinsic and extrinsic
CENTRAL ILLUSTRATION Effect of the Contact Phase Inhibitor Ixodes ricinus Contact Phase Inhibitor in the
Cardiopulmonary Bypass Efficacy Model, and Safety Assessment
Pireaux, V. et al. J Am Coll Cardiol. 2019;74(17):2178–89.
A, Venous reservoir; B, oxygenator; C, heart-lung machine; D, arterial cannula; and E, venous cannula.
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Author's Personal Copypathways of coagulation. This may be explained by
the potential inhibitory effect of Ir-CPI on retro-
activation of the contact phase by thrombin known to
amplify the thrombin generation process in the
presence of tissue factor (28).
Hemorrhage is the primary complication of anti-
coagulation therapy during CPB, even whenanticoagulants are maintained within their therapeu-
tic margin (1,2). Given that Decrem et al. (21) already
showed that Ir-CPI did not induce bleeding in rodent
tail transection assays, we assessed the safety of Ir-CPI
in a liver bleeding assay performed in pigs (Central
Illustration). This species is widely used for evalua-
tion of the hemostatic performance of drugs because of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Extracorporeal circulation during CPB is associated
with thrombin generation, and high-dose heparin is
needed to suppress thrombus formation. In animal
models of CPB and liver injury, Ir-CPI, a specific in-
hibitor of coagulation factors XIa and XIIa, prevents
thrombosis with less hemorrhagic risk than heparin.
TRANSLATIONAL OUTLOOK: Clinical studies are
needed to evaluate the safety and efficacy of Ir-CPI
and other factors XI and XII inhibitors as alternatives
to heparin during CPB.
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Author's Personal Copyits size and similarity to humans with respect to the
coagulation system (29–32). Moreover, anatomically
the porcine liver is more easily accessible than the
ovine liver. Using individual pigs, we showed that Ir-
CPI is a safe thromboprotector with a very limited ef-
fect on bleeding, whereas UFH induced significant
blood loss. Likewise, the interindividual variability in
volume of blood collected was considerably higher
with UFH than with Ir-CPI, as some animals presented
significant bleedings whereas others had blood col-
lections within normal limits. This observation may be
of relevance to clinical findings with UFH (33).
Unlike UFH, Ir-CPI may not require neutralization
when anticoagulation is no longer needed because it
has a short distribution half-life (e.g., 40min in rabbits)
defining its period of activity. On the contrary, when
UFH is used, administration of protamine sulfate is
needed to quickly neutralize the antithrombin
mediated-anticoagulant properties of UFH at the end
of surgery in order to prevent any hemorrhagic events.
However, clinical use of protamine is associated with
safety concerns, including thrombocytopenia and
potentially life-threatening anaphylactic complica-
tions with critical symptoms such as severe hypoten-
sion, cardiovascular collapse, pulmonary edema,
pulmonary vasoconstriction, and pulmonary hyper-
tension (34,35). Furthermore, prospective randomized
trials have shown that protamine administration for
UFH neutralization is associated with increased
bleeding, particularly after cardiothoracic surgery
with CPB (36,37).
STUDY LIMITATIONS. Although animal models
represent the only rational approach for preclinical
studies, they might not fully predict the pharmaco-
logical response to Ir-CPI exposure in humans. For
example, during in vitro assays, plasma from animal
species in this study presented a limited response to
Ir-CPI in terms of FXII and/or FXI inhibition and/or
prolongation of aPTT compared to human plasma
(data not shown). Nevertheless, in vivo, Ir-CPI was
efficient in inhibiting thrombus formation in all
models studied.
Due to anatomic constraints, the liver bleeding
assay could not be performed in the same species as
that used for the efficacy model. Moreover, evalua-
tion of the safety of molecules using documented
bleeding assays does not always reflect the situation
that will be encountered in humans. However, results
obtained in the pig bleeding assay are consistent with
data reported in the literature showing that FXII in-
hibition and, in some instances, FXI inhibition are not
associated with a bleeding tendency (6–11). Even if
tissue factor as well as FXII activation on the poly-
anionic surface of medical devices might triggerthrombosis during CPB, no assessment of the specific
role of this factor was performed here. Although not
reported to inhibit the extrinsic pathway in vitro,
other experiments are required to investigate
whether Ir-CPI could interfere with this pathway
in vivo. Finally, as with any foreign therapeutic pro-
tein, there is a risk that Ir-CPI might be immunogenic.
Nevertheless, the relevance and impact of this
immunogenicity, if any, must be carefully evaluated
during preclinical toxicology and safety studies.
CONCLUSIONS
To the best of our knowledge, this is the first time that
an inhibitor of both FXIa and FXIIa has been shown to
provide thromboprotection during CPB in cardiac
surgery, to have no clinical impact on the recovery of
animals, and to be safer than UFH in terms of
bleeding. Such preclinical results indicate that Ir-CPI
might be an important therapeutic agent by protect-
ing patients from thrombosis in clinical situations
involving activation of the contact phase but also in
highly inflammatory and thrombogenic procedures
involving both the intrinsic and extrinsic pathways of
coagulation.
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and figures, please see the online version of this
paper.
